GNL Gut and Liver
  1. Hoon Jai Chun, Seun Ja Park, Yun Jeong Lim, Si Young Song. Gastrointestinal Cancer. .
    https://doi.org/10.1007/978-981-99-0815-8_51
  2. Si-qi Yang, Rui-qi Zou, Yu-shi Dai, Fu-yu Li, Hai-jie Hu. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis. Updates Surg 2023
    https://doi.org/10.1007/s13304-023-01626-0
  3. Manoj Amrutkar, Caroline S. Verbeke, Anette Vefferstad Finstadsveen, Linda Dorg, Knut Jørgen Labori, Ivar P. Gladhaug. Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma. Molecular Oncology 2023;17:59
    https://doi.org/10.1002/1878-0261.13344
  4. Raffaello Roesel, Letizia Deantonio, Lorenzo Bernardi, Maria Luisa Garo, Pietro Majno-Hurst, Alberto Vannelli, Marco Cefalì, Maria Celeste Palmarocchi, Maria Carla Valli, Guido Pesola, Alessandra Cristaudi, Sara De Dosso. Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes. Cancers 2023;15:4627
    https://doi.org/10.3390/cancers15184627
  5. Dong Uk Kim. Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?. Gut and Liver 2022;16:3
    https://doi.org/10.5009/gnl210585
  6. G. G. Akhaladze, S. V. Goncharov, V. A. Ragimov, Z. E. Baliev, I. N. Berdnikova, M. A. Ilin, O. P. Bliznyukov. Pancreaticoduodenal resection for primary unresectable pancreatic head cancer after neoadjuvant chemotherapy. Ann. hir. gepatol. 2023;28:110
    https://doi.org/10.16931/10.16931/1995-5464.2023-2-110-116
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd